A 39-year-old woman presented with progressive swelling, pain, and fever of the right hand following a cat bite 42 days earlier. She had systemic lupus erythematosus on methylprednisolone and mycophenolate mofetil and type 1 diabetes managed with continuous insulin infusion. Short-course intravenous ceftriaxone followed by oral clindamycin had been given after an outpatient dermatology diagnosis of cellulitis, but symptoms persisted. On hospital admission investigators reported fever (38.3°C), focal swelling and tenderness, and laboratory evidence of inflammation. White blood cell count and C-reactive protein were elevated. Glycated hemoglobin indicated suboptimal glycemic control. Immunoglobulin assays showed marked hypogammaglobulinemia with levels of IgG, IgA, and IgM well below reference ranges.
Magnetic resonance imaging performed on admission revealed a subcutaneous fluid collection over the dorsum of the hand and osteomyelitis of the third metacarpal bone. An earlier MRI, obtained 31 days before admission, had not shown bone involvement. The timeline therefore suggests an indolent progression from soft-tissue infection to bone involvement despite initial outpatient antibiotics. The clinical team performed incision and drainage and obtained pus, tissue, and blood specimens for culture and molecular testing.
Routine aerobic, anaerobic, and enrichment cultures of pus and tissue were negative; blood cultures were likewise unrevealing. Serologic testing for Bartonella returned negative. Because empirical β-lactam/β-lactamase inhibitor regimens failed to produce improvement, the investigators pursued molecular identification. On hospital day 11, 16S rRNA gene sequencing of DNA from a tissue specimen identified Metamycoplasma gateae. The reported sequence matched reference entries with 99.86% identity and was deposited in GenBank (accession no. LC934417). The authors noted the nearest alternate match was Mycoplasma arginini (99.31% identity), and they acknowledged that they did not perform whole-genome sequencing, so misclassification could not be fully excluded.
Empirical therapy began with piperacillin/tazobactam. Treatment was changed to ampicillin/sulbactam on day 5 because of ongoing symptoms and then reverted to piperacillin/tazobactam on day 8 when pain worsened. After molecular identification of M. gateae and persistent swelling on day 12, clinicians initiated minocycline 100 mg every 12 hours. The clinical team selected minocycline because of its bone penetration properties; the report states no standardized human treatment regimens for M. gateae exist. By day 19 the patient showed reduced erythema and swelling and improved range of motion. She was discharged on hospital day 29 with instructions to continue oral minocycline for more than four weeks.
Investigators emphasized the patient’s immunocompromised status—chronic corticosteroid use, mycophenolate, and hypogammaglobulinemia—as likely contributors to susceptibility. The report cites existing literature that hypogammaglobulinemia is a known risk factor for Mycoplasma infections. The authors also described M. gateae as commonly present in domestic cats; prior work cited in the article reports a high prevalence in adult cats. In veterinary medicine M. gateae has been associated with erosive polyarthritis, tenosynovitis, ulcerative keratitis, and lower respiratory tract disease in cats, especially when feline hosts are immunocompromised.
The case highlights several diagnostic and therapeutic gaps. Routine cultures were negative despite clear clinical infection; the team noted that prior antimicrobial exposure may have reduced culture yield and masked other pathogens. Molecular identification required 16S rRNA sequencing because specialized culture of Mycoplasma-like organisms is not part of standard workflows in many labs. The authors reported they did not perform whole-genome sequencing and therefore could not entirely exclude misclassification between closely related species. No standardized antimicrobial regimens for human M. gateae infection have been established; the treating clinicians chose minocycline empirically for its bone penetration and observed subsequent clinical improvement. Investigators recommended that clinicians consider M. gateae in immunocompromised patients with cat-bite exposure when routine cultures are negative and β-lactam/β-lactamase inhibitor therapy is ineffective.
Reported unanswered questions and practical next steps include: whether alternative or combination antimicrobial regimens would offer superior outcomes, how frequently human infections are missed because of culture-negative results, and whether routine use of specialized Mycoplasma culture or earlier molecular testing should be recommended after cat-bite exposures in immunocompromised hosts. The authors also documented the limitation that lack of whole-genome sequencing leaves residual uncertainty about exact species assignment.